ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously ...

ANI Pharmaceuticals, Inc. ("ANI" or "the Company") (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced ...

ANI Pharmaceuticals (ANIP)  said it completed its planned acquisition of Alimera Sciences (NASDAQ:ALIM). Under the terms of ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals (ANIP – Research Report), ...

Alimera Sciences (NASDAQ:ALIM) plummeted 25% in premarket trading after it said it filed a lawsuit against ANI ...

Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds ...

PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the ...

PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company ...

On June 24, ANI said it was buying Alimera Sciences for $5.50 per share in cash, in a deal that valued Alimera at $381 million. The offer represented a 75% premium to its closing share price of $3.15 ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

ANI Pharmaceuticals acquiring Alimera Sciences for $5.50 per share with potential for $0.50 per share CVR, offering an ...

Alimera’s lawsuit asks the court to require ANI to comply with its obligations to complete the transaction as contemplated by ...